title: alpha3beta1 integrin induced suppression of the Caco-2 epithelial cell IL-1 signaling pathway leading to NF-(kappa)B activation.
abstract: Intestinal epithelial cells (IECs) produce several potent cytokines in response to interleukin-1 (IL-1) and may play a role in the inflammatory response. Previously, we determined that treatment of the Caco-2 cells with a cross-linking anti-alpha3 integrin antibody resulted in a suppression of IL-1 induced cytokine secretion and mRNA levels, suggesting that the alpha3beta1 integrin may play a role in the regulation of IEC cytokine responses to IL-1. In this report, treatment of the Caco-2 cells with the anti-alpha3 integrin antibody resulted in a suppression of IL-1 induced levels of NF-kappaB binding activity in nuclear extracts, as determined by EMSA, as well as phosphorylation and degradation of the inhibitor, I(kappa)B(alpha). The anti-integrin antibody treatment was also found to suppress I(kappa)B kinase (IKK) activity and IKK(beta) phosphorylation. Culture of the Caco-2 cells on purified laminin-5, the ligand for the alpha3beta1 integrin, also resulted in suppression of IL-1 induced phosphorylation of I(kappa)B(alpha) and IKK(beta). Together with our previous findings, these results suggest that alpha3beta1 integrin binding results in a suppression of the IL-1 signaling pathway leading to the activation of NF-(kappa)B and ultimately IEC cytokine responses. These studies define a novel regulatory mechanism which may be important in the control of IEC cytokine responses during inflammation.
authors.affiliation: Department of Biological Sciences, Binghamton University (SUNY), Binghamton, NY 13902-6000, USA.
authors.forename: Gongchu
authors.initials: G
authors.lastname: Li
authors.forename: Farah D
authors.initials: FD
authors.lastname: Lubin
authors.forename: Dennis W
authors.initials: DW
authors.lastname: McGee
mesh_terms: D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D018938:Caco-2 Cells; D002457:Cell Extracts; D002467:Cell Nucleus / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D051550:I-kappa B Kinase; D020672:I-kappa B Proteins / Q000378:metabolism; D039201:Integrin alpha3beta1 / Q000819:agonists / Q000276:immunology / Q000378:metabolism*; D007375:Interleukin-1 / Q000276:immunology*; D007797:Laminin / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013379:Substrate Specificity
chemical_list: D000906:Antibodies; D002457:Cell Extracts; D005353:Fibronectins; D020672:I-kappa B Proteins; D039201:Integrin alpha3beta1; D007375:Interleukin-1; D007797:Laminin; D016328:NF-kappa B; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human